綠葉製藥(02186.HK)擬發行3億元可轉換債券 初步換股價溢價約54.2%
格隆匯9月2日丨綠葉製藥(02186.HK)公吿,於2022年9月2日,公司與認購人新葉生物醫藥控股有限公司訂立認購協議,公司已有條件同意向認購人發行本金額為人民幣3億元等額港元的可轉換債券,假設債券全部按每股股份的初步換股價3.50港元(較股份於2022年9月1日收市價每股2.27港元溢價約54.2%)進行轉換,並且不再發行其他股份,債券將轉換成最多9915萬股股份,約佔公司截至本公吿日期已發行股本的2.79%及約佔公司在債券全部轉換下發行轉換股份後經擴大的已發行股本的2.72%。
債券所得款項淨額估計為約3.42億港元,集團擬將發行債券所得款項淨額用於注資至集團資本支出及(特別是)更新集團於四川、南京及煙台的設施;及為該等設施購買設備。集團預期債券所得款項淨額當中約43.3%、40.0%及16.7%將分別用於集團在四川、煙台及南京的設施,並預期將於2024年底前完成有關資本支出。
董事會認為,發行債券將按合理成本為公司提供額外資金,以為其持續業務發展提供資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.